Current Edition


  • Revita is a non-drug, minimally-invasive therapeutic procedure for type 2 diabetes that improves blood sugar control
  • The one-hour, same-day treatment targets the duodenal lining (in the upper intestine) – triggering the body’s cell regeneration process
  • By improving insulin sensitivity, and enabling better use of the body’s own natural insulin, Revita offers a new way to avoid insulin injections for those currently uncontrolled on oral medications
  • The Princess Grace Hospital, part of HCA Healthcare UK is the first medical facility in the world to offer Revita to self-pay patients

Revita, a breakthrough treatment for type 2 diabetes (T2D), is now available at The Princess Grace Hospital, part of HCA Healthcare UK.  The Princess Grace Hospital in London is the first medical facility in the world to offer Revita to self-pay patients.  

Revita is a minimally invasive procedure that is performed endoscopically to target the duodenum, a precise area of the intestine that plays a critical role in metabolic pathways including insulin resistance. This non-drug and non-surgical alternative has been shown to enhance insulin sensitivity, lower HbA1c and create long lasting improvements in blood sugar control to help avoid further medication escalation[1].

Coupled with continued healthy diet and exercise, a single Revita treatment can last up to 24 months or more and is ideal for anyone with a busy lifestyle, where additional daily medications for T2D can be a burden.

T2D is a progressive disease, which can cause complications such as heart disease, stroke, liver and kidney damage. There are 3.8 million people living with T2D in the UK, and the number diagnosed has more than doubled over the last 20 years[2]. People with T2D may attempt to control blood glucose levels with lifestyle changes and medications, but when these are ineffective patients may face daily insulin injections. Patients who are looking for alternatives to adding more daily medications, including insulin[3], may find that Revita offers a unique, non-drug alternative with compelling benefits beyond blood sugar control.

The announcement that Revita is now commercially available for patients for the first time ever comes following a series of global clinical trials on the procedure, involving close to 300 patients, and including the involvement of four NHS hospitals.

Dr David Hopkins, Consultant Physician and Diabetologist at King’s College Hospital and lead investigator in the Revita-2 clinical trial comments:

Revita is a pioneering treatment which could radically change the course of type 2 diabetes, for patients individually and at a population level. While there are increasing pharmacological T2D treatments, these have not translated into meaningful improvements in patient outcomes. By targeting insulin resistance in the duodenum – the root cause of metabolic disease – the Revita procedure has considerable benefits and may help the person to avoid escalating drug treatment.”

The research published to date shows five important metabolic benefits for patients: improved overall insulin sensitivity, lowered HbA1c (by nearly 1%), moderate weight loss, improved liver health (over 35% reduction in liver fat, a key factor in the development of liver disease*) and increased ‘good’ (HDL) cholesterol (a parameter that correlates with a reduction of CV risk)[4].

Revita is now available to self-pay patients at The Princess Grace Hospital, part of HCA Healthcare UK. It is provided as part of a programme of care for patients with T2D, including the procedure itself as well as consultations and post-procedure support. This complete pre and aftercare programme helps patients adjust to a healthier lifestyle post-procedure, with specialist follow up appointments for diabetes and dietary advice, as needed.

Dr Bu Hayee, Consultant Gastroenterologist at The Princess Grace Hospital comments:

We believe that the new Revita procedure will be a game changer for many patients who struggle to control their blood sugar levels despite dietary and lifestyle changes and will offer a great alternative to conventional drug therapies. We know that T2D is a progressive disease, which can cause complications such as heart disease, stroke, liver and kidney damage. The arrival of Revita will offer new hope to these patients that the symptoms of the disease can be reversed. Patients can go home the same day, following treatment, with minimal side effects – it really is a unique option.”

Miranda Dodd, CEO of The Princess Grace Hospital says of the treatment’s arrival:

“We are excited to be the first medical facility in the world to be able to offer the Revita procedure to our patients with T2D. At The Princess Grace, we always strive to provide the most innovative and ground-breaking treatments for our patients – giving them access to world-leading personalised health care. Led by a specialist team of experts, our hope is that Revita will allow patients all over the UK – and internationally – to take back control of their lives with a single treatment.”

Russell Pearson, from Essex, was one of the early clinical trial patients in the UK, having undergone the procedure in London three years ago. Russell recently commented:

“Before my Revita procedure I was taking two diabetes tablets and my GP was concerned I might have to take insulin in the future. After Revita my blood sugar improved for the first time in years and I have also reduced my daily medication. My recent blood test shows my levels are now better than the pre-diabetic range.”**

For more information visit: or 

To book a consultation with The Princess Grace Hospital please contact us at and +44 020 3993 4038

*Liver fat is a known key factor for the development of non-alcoholic fatty liver disease, steatohepatitis and liver cirrhosis, one of the main causes for liver transplantation

** Results may vary between patients

About Revita

Revita has been designed to treat the surface of the small intestine, to make way for new, healthy cells to regenerate. This can restore the body’s own ability to manage diabetes. The minimally-invasive, incision-free and implant-free procedure uses a process called ‘Duodenal Mucosal Resurfacing’ (DMR) delivered via endoscopy. Close to 300 patients have had the procedure to date and it has been shown that Revita can cause a clinically significant and durable reduction in their blood sugar levels. The results have been published in Diabetes Care, a leading diabetes journal[5] and Gut the leading gastroenterology journal in the UK[6].

About The Princess Grace Hospital

The Princess Grace Hospital is recognised as one of the UK’s best-equipped, multidisciplinary, acute private hospitals, offering access to the latest innovative technology and pioneering medical treatment for Breast Care, Oncology, Orthopaedics, Gastroenterology, Urology and Sports Medicine.

The Princess Grace Hospital is constantly at the forefront of medical innovation, we were the first private hospital to conduct and offer digital mammography, the first to have an Urgent Care Centre and the first in the UK to offer the MAKO robotic orthopaedic procedures, and robotic prostatectomies.

We are also part of an elite group of hospitals in the world, specialising in cancerous tumour ablation, for inoperable conditions through our NanoKnife technology.

Our world-class units include: The London Breast Institute, The London Digestive Centre, The London Orthopaedics Centre, London Urology Centre and The Institute of Sports, Exercise and Health.

About Fractyl

Fractyl Laboratories is a private biotechnology company based in Lexington, Massachusetts, USA. Fractyl has developed Revita, a same-day, minimally-invasive procedural therapy to treat highly prevalent metabolic diseases. The Revita procedure harnesses breakthrough insights in intestinal biology and leverages the body’s inherent regenerative capacity to reverse insulin resistance and metabolic diseases. Fractyl’s approach aims to improve the health of patients with metabolic diseases with device-based interventions for patients and healthcare systems. The Revita DMR System received a CE mark in the European Union in April 2016. It has been approved for investigational use by the Food and Drug Administration (FDA) in the United States. The Revita DMR System may be available for investigational use in other regions. For more information, visit or

About HCA Healthcare UK

HCA Healthcare UK includes London Bridge Hospital, The Portland Hospital, The Harley Street Clinic, The Lister Hospital, The Princess Grace Hospital, The Wellington Hospital, Roodlane Medical Ltd, and Blossoms Healthcare.  HCA UK also partners with leading NHS Trusts to provide care at The Christie Private Care, HCA UK at University College Hospital and Private Care at Guy’s.

[1] Van Baar ACG et al. Gut Epub ahead of print; 2019, 0:1–9.



[4] Rajagopalan, et al. Diabetes Care, 2016;39:1–8

[5] Rajagopalan, et al. Diabetes Care, 2016;39:1–8

[6] Van Baar ACG et al. Gut Epub ahead of print; 2019, 0:1–9.